XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Other Accumulated Deficit
At The Market Offering
Total
Balance, beginning of period at Dec. 31, 2020 $ 6 $ 1,058,823 $ (46) $ (665,197)   $ 393,586
Balance, beginning of period (in shares) at Dec. 31, 2020 62,563,457          
Statement of Stockholders' Equity (Deficit)            
Issuance of common stock for public offering $ 1 249,458       249,459
Issuance of common stock for public offering (in shares) 4,025,000          
Issuance of common stock for success payment   27,500       27,500
Issuance of common stock for success payment (in shares) 303,599          
Exercise of stock options   12,002       12,002
Exercise of stock options (in shares) 501,162          
Vesting of restricted common stock awards (in shares) 79,397          
Stock-based compensation expense   12,204       12,204
Unrealized loss on marketable debt securities     (27)     (27)
Net loss       (56,728)   (56,728)
Balance, end of period at Mar. 31, 2021 $ 7 1,359,987 (73) (721,925)   637,996
Balance, end of period (in shares) at Mar. 31, 2021 67,472,615          
Balance, beginning of period at Dec. 31, 2021 $ 7 1,411,827 (493) (857,699)   553,642
Balance, beginning of period (in shares) at Dec. 31, 2021 68,435,257          
Statement of Stockholders' Equity (Deficit)            
Issuance of common stock for public offering (in shares)         0  
Exercise of stock options   218       218
Exercise of stock options (in shares) 12,573          
Vesting of restricted common stock awards (in shares) 154,834          
Stock-based compensation expense   11,431       11,431
Unrealized loss on marketable debt securities     (2,016)     (2,016)
Net loss       (50,515)   (50,515)
Balance, end of period at Mar. 31, 2022 $ 7 $ 1,423,476 $ (2,509) $ (908,214)   $ 512,760
Balance, end of period (in shares) at Mar. 31, 2022 68,602,664